Sign In
Buy SKYE
$0.770
+0.0563 (+7.89%)
At Close: Jun 03, 2026
Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerability Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric a
Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
09:45am, Wednesday, 10'th Sep 2025
Skye Bioscience, Inc. (NASDAQ:SKYE ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:00 AM EDT Company Participants Punit Dhillon - President, CEO, Secretary & Director Co
Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data
01:35pm, Friday, 05'th Sep 2025
On Thursday, Skye Bioscience Inc. SKYE reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.
Skye shares new preclinical DIO data at virtual KOL event Nimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment we
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
07:00am, Tuesday, 02'nd Sep 2025
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and ot
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
07:00am, Wednesday, 27'th Aug 2025
Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025 Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
07:00am, Thursday, 21'st Aug 2025
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and oth
Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript
08:36pm, Thursday, 07'th Aug 2025
Skye Bioscience, Inc. (NASDAQ:SKYE ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kaitlyn Melanie Arsenault - Chief Financial Officer Puneet S. Arora - Chief Medical
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
04:01pm, Thursday, 07'th Aug 2025
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that mo
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
07:00am, Wednesday, 30'th Jul 2025
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and oth
Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing
11:59pm, Monday, 07'th Jul 2025
Skye Bioscience's Nimacimab remains a promising peripheral CB1 antibody for obesity with lean-mass preservation and fewer GI issues. Nimacimab's Phase 2a topline is expected by Q3-Q4 2025, which is it
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and oth
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions
07:00am, Tuesday, 17'th Jun 2025
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and oth
Squarepoint Ops LLC Buys Shares of 13,546 Skye Bioscience, Inc. (NASDAQ:SKYE)
03:36am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC bought a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exc
Squarepoint Ops LLC Takes Position in Skye Bioscience, Inc. (NASDAQ:SKYE)
03:36am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC acquired a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SE
